Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 5,841,591	$ 5,794,272
Short-term investment securities	4,287,325	6,847,270
Interest receivable	36,053	58,285
Accounts receivable	767,597	330,001
Prepaid expenses and other current assets	136,152	392,236
Total current assets	11,068,718	13,422,064
Non-current assets:
Investment in Alphazyme	0	284,709
Other assets	5,822	6,045
Total assets	11,074,540	13,712,818
Current liabilities:
Accounts payable	905,876	1,276,313
Accrued expenses	909,482	955,081
Deferred research and development obligations	9,000	40,743
Deferred license revenue, current portion	176,471	176,471
Total current liabilities	2,000,829	2,448,608
Deferred license revenue, net of current portion	88,235	176,471
Total liabilities	2,089,064	2,625,079
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding	0	0
Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 41,064,563 and 40,816,602, outstanding shares - 28,811,061 and 28,563,100 as of June 30, 2023, and December 31, 2022, respectively	41,065	40,817
Additional paid-in capital	104,465,590	103,458,697
Treasury stock, shares held at cost - 12,253,502	(18,929,915)	(18,929,915)
Accumulated deficit	(76,591,264)	(73,481,860)
Total stockholders’ equity	8,985,476	11,087,739
Total liabilities and stockholders’ equity	$ 11,074,540	$ 13,712,818